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A B S T R A C T
Objectives: Linezolid is a synthetic oxazolidinone antibiotic frequently used to treat vancomycin-resistant
enterococcal infections. Vancomycin-susceptible Enterococcus faecalis can develop resistance to linezolid
in environments with excessive linezolid use. The aim of this study was to define risk factors and outcome
associated with the acquisition of linezolid-resistant E. faecalis (LREfs).
Methods: A retrospective case–control study was designed including patients hospitalised from January
2014 to October 2017 at Hospital Civil de Guadalajara ‘Fray Antonio Alcalde’ in Guadalajara, Mexico. A
total of 50 patients culture-positive for LREfs and 100 control patients hospitalised in the same room and
time as the cases were included. Clinical and demographic data were collected and analysed.
Results: Risk factors for the presence of LREfs included prior linezolid use [odds ratio (OR) = 6.74], prior
clindamycin use (OR = 6.72) and previous surgery (OR = 5.79). The mortality rate was 18% for LREfs cases
versus 9% for controls.
Conclusion: LREfs has emerged and spread in our hospital, an environment in which linezolid use is
considerable. Risk factors for LREfs are prior antibiotic use, including linezolid, and previous surgery.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Enterococci, notably Enterococcus faecium and Enterococcus
faecalis, are common healthcare-associated pathogens, with E.
faecalis being more frequent (85–90%) than E. faecium (10–15%).
These bacterial species are frequently recovered from severely ill
patients who have received multiple antibiotics and experienced
prolonged hospitalisation [1].
Enterococci are intrinsically resistant to several antibiotics, a
trait that is seen more frequently in E. faecium than in E. faecalis.
The inherent resistance mechanisms of enterococci make them
resistant to antibiotics such as aminoglycosides, β-lactams,
cephalosporins and lincosamides [2,3]. The appearance and
dissemination of vancomycin-resistant enterococci has resulted* Corresponding author.
E-mail address: rayomorfin@gmail.com (R. Morfín-Otero).
http://dx.doi.org/10.1016/j.jgar.2020.01.010
2213-7165/© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Soc
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).in the need for new modalities of treatment, with linezolid being
one option [4].
Enterococci can develop resistance during treatment, including
to linezolid, daptomycin and vancomycin [5]. Although seen as less
capable of developing resistance, E. faecalis has evolved to become
a multidrug-resistant bacterium, including to linezolid [6].
Linezolid resistance in enterococci was first reported in 2002
from the UK in two E. faecium and one E. faecalis with linezolid
minimum inhibitory concentrations (MICs) of 64 mg/L that were
obtained from patients with prior exposure to linezolid [7]. In the
following years there have been multiple reports of this
phenomenon, including two cases of linezolid-resistant E. faecalis
(LREfs) obtained from patients who previously received linezolid
for the treatment of infections caused by vancomycin-resistant E.
faecium [8], in patients who received prolonged (>30 days) courses
[9], from Spain [10], Mexico [11] and Brazil in E. faecalis also
resistant to vancomycin [12], in patients receiving prolonged
courses of linezolid for the treatment of mycobacterial infections
[13,14], and of 26 E. faecalis found to be linezolid-resistant (with 24iety for Antimicrobial Chemotherapy. This is an open access article under the CC BY-
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faecalis isolates [15]. Nosocomial outbreaks began to occur in
various countries [16–18]. In a 5-year surveillance study from
2011–2015, the relationship between antibiotic consumption and
linezolid resistance in E. faecalis was studied [19]. The increasing
annual detection of LREfs correlated with an increase in use of
linezolid measured as defined daily doses (DDD) per 100 bed-days
[19].
The aim of the current study was to define risk factors and
outcomes associated with the acquisition of LREfs.
2. Methods
2.1. Study design
A retrospective case–control study among patients hospitalised
from January 2014 to October 2017 at Hospital Civil de Guadalajara
‘Fray Antonio Alcalde’ (Guadalajara, Jalisco, Mexico) was designed.
During this period, 50 case patients culture-positive for LREfs and
100 control patients hospitalised in the same room and time as
the cases (i.e. two controls per case) were evaluated. Control
patients were selected from the same source population as
the case patients. The control patients were admitted during the
same period as the case patients and were hospitalised in the
same hospital service in which case patients were located to
prevent biased estimates of relative risk that occurs when one
decides patients with positive cultures for susceptible bacteria as
the control group [20,21]. Patients hospitalised for <48 h were
excluded. ‘Risk time’ was defined as the number of days from
admission to being diagnosed with a positive culture; for controls,
exposure data were collected from the date of admission until the
date of discharge or death.
The National Healthcare Safety Network of the US Centers for
Disease Control and Prevention (CDC/NHSN) surveillance defini-
tions of healthcare-associated infection were used, as follows: for
skin and soft-tissue infection and surgical wound infection, the
presence of purulent drainage; for bloodstream infection, bacteria
isolated from a blood culture bottle; for intra-abdominal infection,
a positive culture from purulent material obtained during surgery;
for urine tract infection, the presence of fever and a positive urineTable 1
Characteristics of cases patients infected with linezolid-resistant Enterococcus faecalis a
Characteristic Cases (N = 50) 
Sex (male/female) 23 (46)/27 (54)
Age (years) (mean  S.D.) 44.54  25 
Length of stay (days) (mean  S.D.) 35.0  33.3 
Risk time (days) (mean  S.D.) 12.42  15.1 
Charlson comorbidity index (mean  S.D.) 2.2  2.1 
Previous hospitalisation 20 (40) 
Previous surgery 15 (30) 
ICU stay 10 (20) 
Central venous catheter 18 (36) 
Mechanical ventilation 15 (30) 
Urinary catheter 25 (50) 
Parenteral nutrition 15 (30) 
Acute kidney disease 13 (26) 
Antibiotic use in previous 30 days 40 (80) 
Third-generation cephalosporins 25 (50) 
Meropenem 15 (30) 
Linezolid 18 (36) 
Clindamycin 17 (34) 
Fluoroquinolones 8 (16) 
Amikacin 10 (20) 
Vancomycin 3 (6) 
Colistin 6 (12) 
S.D., standard deviation; ICU, intensive care unit.
a Data are n (%) unless otherwise stated.
b Significant P-values are shown in bold.culture; and for respiratory tract infection, the presence of fever,
leukocytosis, increase in respiratory secretions and tachypnoea.
Data obtained from the medical records, demographic infor-
mation, previous hospitalisation, prior use of antibiotics and time
of discharge were included. The Charlson comorbidity index was
used to evaluate patients co-morbidities. Use of linezolid was
determined as the DDD/100 bed-days.
2.2. Data and analysis
Clinical data were collected from the clinical records for cases
and controls. Calculations were conducted to determine the
Charlson comorbidity index. Species Identification and antimicro-
bial susceptibility were determined using a VITEK12 automated
system (bioMérieux, Lyon, France). The criteria of the Clinical and
Laboratory Standards Institute (CLSI) were used for interpretation
of the results of antimicrobial susceptibility testing. A linezolid MIC
 8 mg/mL was considered resistant. Data were analysed using IBM
SPSS Statistics v.24.0 (IBM Corp., Armonk, NY, USA), with logistic
regression analysis conducted to calculate the odds ratio (OR). The
t-test was used for independent variables and the χ2 test was to
evaluate differences between groups, with a P-value of <0.05
considered statistically significant.
2.3. Ethics statement
This study was approved by the local ethics, research and
biosafety committee of the University of Guadalajara (Guadalajara,
Mexico).
3. Results
LREfs was recovered from skin and soft tissues in 32% of case
patients, followed by blood (19%), intra-abdominal (16%), urine
(14%), surgical wound (13%) and respiratory specimens (6%).
Table 1 describes the characteristics of the 50 cases and 100
controls. Case patients had a longer mean length of stay compared
with controls (35.0 days vs. 11.1 days; P < 0.001), with a risk time
for cases of 12.42 days. Risk factors for LREfs included hospital-
isation in the previous 6 months (40% vs.15%; P = 0.001), stay in thend controls.a
Controls (N = 100) P-valueb
 55 (55)/45 (45) 0.298
36.97  22.6 0.227
11.1  10.1 <0.001
10.57  9.8 0.110
1.46  1.8 0.114
15 (15) 0.001
5 (5) <0.001
8 (8) 0.033
23 (23) 0.092
17 (7) 0.067
29 (29) 0.012
10 (10) 0.002
5 (5) <0.001
65 (65) 0.021
29 (29) 0.006
6 (6) <0.001
6 (6) <0.001
8 (8) <0.001
9 (9) 0.171
7 (7) 0.013
4 (4) 0.546
0 <0.001
Table 2
Multivariate analysis of risk factors associated with linezolid-resistant Enterococcus faecalis infection.
Characteristic n (%) OR (95% CI) P-valuea
Cases (N = 50) Controls (N = 100)
Previous hospitalisation 20 (40) 15 (15) 2.85 (0.944–8.62) 0.63
Previous surgery 15 (30) 5 (5) 5.79 (1.58–21.14) 0.008
Urinary catheter 25 (50) 29 (29) 0.760 (0.25–2.25) 0.620
Parenteral nutrition 15 (30) 10 (10) 3.45 (0.9–13.26) 0.071
Previous use of meropenem 15 (30) 6 (6) 1.11 (0.22–5.63) 0.895
Previous use of linezolid 18 (36) 6 (6) 6.74 (1.56–29.04) 0.01
Previous use of clindamycin 17 (34) 8 (8) 6.72 (2.23–20.19) 0.001
OR, odds ratio; CI, confidence interval.
a Significant P-values are shown in bold.
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(30% vs. 5%; P < 0.001), presence of a urinary catheter (50% vs. 29%;
P = 0.012), parenteral nutrition (30% vs. 10%; P = 0.002) and acute
kidney disease (26% vs. 5%; P < 0.001).
In additional, use of antibiotics in the previous 30 days was
significantly higher among case patients, including third-genera-
tion cephalosporins, meropenem, linezolid, clindamycin, amikacin
and colistin (Table 1).
In the multivariate analysis of risk factors, LREfs was more
frequent in patients with previous surgery (OR = 5.79), previous
use of linezolid (OR = 6.74) and previous use of clindamycin (OR =
6.72) (Table 2).
All E. faecalis isolates were resistant to linezolid and over one-
half of the isolates (56%) were resistant to levofloxacin, whereas
98% were susceptible to vancomycin, 80% were susceptible to
ampicillin and 72% were susceptible to high-level gentamicin. The
mortality rate was 18% for LREfs cases versus 9% for controls (P =
0.003). The DDD of linezolid in our hospital for the years 2014–
2017 was 1.2, 5.1, 3.1 and 6.3, respectively.
4. Discussion
Infection with drug-resistant bacteria, including LREfs, is
emerging as an important challenge in healthcare settings
[3,22,23]. The need for adequate control policies on antibiotic-
resistant bacteria became apparent when resistant bacteria began
to achieve prominence in outbreaks [24].
This report describes the association of several risk factors with
the development of LREfs infection.
Vancomycin resistance in enterococci was first described in
1988 and it has since been clinically encountered frequently both
in community and nosocomial infections [4]. The predominant
mechanism of linezolid resistance in enterococci involves the
G2576T mutation in the 23S rRNA gene. Other mechanisms that
have been reported are mutations in the L3 and L4 ribosomal
proteins as well as two plasmid-borne genes (cfr and optrA) [1]. The
cfr gene was first reported in 2000 in Staphylococcus sciuri [25], and
linezolid-resistant enterococcal infections began to be detected
among vancomycin-resistant E. faecium nosocomial infections,
causing dissemination and outbreaks [26–29].
Prior use of linezolid was one the most significant risk factors
for LREfs infection identified in this study, similar to the findings
of previous reports. ICU outbreaks of linezolid-resistant entero-
cocci, including LREfs, have occurred in the setting of prolonged
linezolid treatment courses [13,16,18]. Among the risk factors
significantly associated with the presence of a linezolid-resistant
Enterococcus spp. is previous linezolid use, specifically its
prolonged use [30,31].
Other risk factors for infection with linezolid-resistant Entero-
coccus spp. include immunosuppression, neutropenia and invasive
procedures [32]. In the cases in the current study, primary riskfactors included previous antibiotic use, mainly linezolid, as well as
invasive procedures, previous hospitalisation and surgery.
Linezolid resistance can be acquired by many bacterial species
through horizontal gene transfer [33–35]. The cfr gene was first
documented in our hospital in 2009 in three linezolid-resistant
staphylococcal isolates, all of which were susceptible to tetracy-
cline, tigecycline, daptomycin and vancomycin [36]. In our
hospital, linezolid resistance in Staphylococcus epidermidis and
Staphylococcus cohnii [36] and in E. faecalis [11] was detected
around the same time, which may suggest that the cfr gene present
in staphylococci likely acted as a reservoir for this resistance.
Linezolid was approved for clinical use in 2000 in the USA, 2
years after its approval for human consumption in Mexico. During
the past 17 years, linezolid consumption in our hospital has
continuously increased secondary to its use in the treatment of
tuberculosis (TB) as one of the intravenous drugs used when the
oral route is not available. The duration of the initial stabilisation
period is 15–30 days, a risk factor similar to a report in 2018 that
prior to the isolation of LREfs the mean linezolid treatment
duration was 29.8  48.8 days [19] and to the prolonged linezolid
exposure also documented in 2004 and 2017 [9,14].
In hospitals where both vancomycin-resistant enterococci and
linezolid-resistant enterococci coexist, extreme care should be
taken in choosing the best treatment option [37]. Enterococci
infections can significantly increase the 30-day mortality rate [37].
Linezolid use is substantial in our hospital, particularly in the
initial aggressive treatment of severe forms of TB. This practice
has likely facilitated linezolid resistance in Gram-positive bacteria
[19,38]. In an environment of excessive linezolid use, inappropriate
use of clindamycin can enhance the selective pressure on
enterococci to develop resistance to linezolid [39,40], as clinda-
mycin promotes the development of cfr and cfr-like multiple
resistance genes [40].
Linezolid resistance in E. faecalis is developing in other Mexican
regions. In a recent report of antimicrobial resistance detected in
47 hospital centres in 20 Mexican states, resistance to linezolid
occurred in 7.3% of 892 E. faecalis isolates and 2.4% of 124 E. faecium
isolates [41].
A dedicated antimicrobial stewardship intervention intended to
reduce linezolid use in our hospital is needed. A Spanish hospital
reduced its linezolid consumption by 76% while seeing a reduction
in LREfs isolation after initiating a focused antimicrobial steward-
ship programme [42].
The current study has several limitations, including the lack of
faecal cultures to assess enterococcal carriage and detection of the
linezolid resistance mechanism involved.
5. Conclusions
LREfs has emerged and spread in our hospital in Mexico, an
environment in which linezolid use is considerable. LREfs
408 E. Rodríguez-Noriega et al. / Journal of Global Antimicrobial Resistance 21 (2020) 405–409primarily causes infections in patients with previous hospital-
isation, surgery and linezolid exposure.
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